Azitra, Inc. AZTR
Azitra, Inc. (NYSE: AZTR) is a dermatology drug developer. Its lead program, ATR-04, is in Phase 1 for EGFR-inhibitor-associated papulopustular rash in cancer patients. Its next catalyst on record is ATR-04: Initial data from Cohort 1 of Phase 1/2 trial (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ATR-04 — Initial data from Cohort 1 of Phase 1/2 trial (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ATR-04 | EGFRi-associated rash | biologic-other | Phase 1 |
| ATR-12 | Netherton syndrome | biologic-other | Phase 1 |
| ATR-01 | Ichthyosis vulgaris | biologic-other | Pre-clinical |
| ATR-COSF | Cosmetic ingredient (fine lines and wrinkles) | protein/peptide | NA_NON_THERAPEUTIC |
Recent results and decisions
- Aug 12, 2026n/a Azitra plans to pause further enrollment in the ATR-12 Phase 1b Netherton syndrome study for capital allocation reasons
Azitra plans to strategically pause further enrollment in the ongoing Phase 1b study evaluating ATR-12 for Netherton syndrome.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 dermatology companies
- Arcutis Biotherapeutics, Inc. ARQT
- Absci Corp ABSI
- FibroBiologics, Inc. FBLG
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.